

Special Issue

Polymeric Nanovaccines for Immune Modulation

Message from the Guest Editors

Vaccination is one of the most effective ways to cure human diseases. With the advancements in science and technology, nanovaccines comprising nanoparticles that are either used as adjuvants or carriers has emerged as one of the most effective treatment strategies for health promotion and disease prevention. Nanovaccines are reported to be highly efficient in inducing humoral and cell-mediated immune responses and demonstrate high antigen loading, enhanced immunogenicity, and controlled antigen presentation. Polymers from the natural or synthetic route are often used for developing nanovaccines which could be easily internalized by antigen-presenting cells and exert immune modulations owing to the unique physiochemical properties of nanoparticles. We are calling for manuscripts detailing natural and synthetic polymeric nanovaccines, anticancer nanovaccine delivery systems, immune modulating polymeric nanoparticles, etc. We sincerely hope this Special Issue serves as a platform for the exchange of the latest developments in the field of polymeric nano vaccines.

Guest Editors

Dr. Saji Uthaman

Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA

Prof. Dr. In-Kyu Park

Department of Biomedical Sciences, Chonnam National University Medical School, 160 Baekseo-ro, Gwangju 58128, Korea

Deadline for manuscript submissions

closed (10 March 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/66511

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).